- Cosmos Health announced that its subsidiary, Cana Laboratories, has received new contract manufacturing orders from Nassington and Verisfield totaling 253,657 units.
- The orders cover multiple pharmaceutical products, including oral solutions, tablets, a cutaneous spray, and a rectal cream.
Cosmos Health Inc. has announced that its wholly owned subsidiary, Cana Laboratories, has secured new contract manufacturing orders from Nassington and Verisfield for a combined 253,657 units across a portfolio of pharmaceutical products. The orders expand Cana’s manufacturing activities and add to the company’s contract manufacturing business.
According to the company, Cana will manufacture several products under the agreement, including Gritse oral solution 0.4 mg/ml, Gritse forte oral solutions in 2 mg/ml and 4 mg/ml strengths, Fungofort cutaneous spray, Paco-4 tablets, dexamethasone oral solution in multiple presentations, and Foproct rectal cream.
The orders were awarded to Cana Laboratories, the pharmaceutical manufacturing subsidiary of Cosmos Health. The company stated that the contracts span a range of medicines and pharmaceutical products, supporting its vertically integrated healthcare business model.
“These orders reflect the demand for Cana’s contract manufacturing capabilities and the strength of our vertically integrated platform. By deepening our relationships with established pharmaceutical partners across a broad range of products, we continue to build a diversified manufacturing business that supports long-term value creation for our shareholders.”
Greg Siokas, Chief Executive Officer of Cosmos Health
